{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:41:43Z","timestamp":1790667703542,"version":"4.1.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T00:00:00Z","timestamp":1655251200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.antiviral.2022.105359","type":"journal-article","created":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T01:48:21Z","timestamp":1655516901000},"page":"105359","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Identification of structurally re-engineered rocaglates as inhibitors against hepatitis E virus replication"],"prefix":"10.1016","volume":"204","author":[{"given":"Dimas F.","family":"Praditya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7707-2040","authenticated-orcid":false,"given":"Mara","family":"Kl\u00f6hn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Br\u00fcggemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren E.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"John A.","family":"Porco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Kinast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kirschning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian W.R.","family":"Vondran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Todt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eike","family":"Steinmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2022.105359_bib1","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1055\/a-1401-9562","article-title":"Update on phytochemical and biological studies on rocaglate derivatives from Aglaia species","volume":"87","author":"Agarwal","year":"2021","journal-title":"Planta Med."},{"key":"10.1016\/j.antiviral.2022.105359_bib2","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.antiviral.2016.11.011","article-title":"The natural compound silvestrol is a potent inhibitor of Ebola virus replication","volume":"137","author":"Biedenkopf","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2022.105359_bib3","doi-asserted-by":"crossref","first-page":"5151","DOI":"10.1038\/s41467-019-13086-5","article-title":"eIF4A supports an oncogenic translation program in pancreatic ductal adenocarcinoma","volume":"10","author":"Chan","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.antiviral.2022.105359_bib4","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.chembiol.2019.08.008","article-title":"Amidino-rocaglates: a potent class of eIF4A inhibitors","volume":"26","author":"Chu","year":"2019","journal-title":"Cell Chemical Biology"},{"key":"10.1016\/j.antiviral.2022.105359_bib5","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1016\/j.celrep.2020.02.002","article-title":"Rocaglates induce gain-of-function alterations to eIF4A and eIF4F","volume":"30","author":"Chu","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.antiviral.2022.105359_bib6","unstructured":"ClinicalTrials.gov, 2021. NTC04632381."},{"key":"10.1016\/j.antiviral.2022.105359_bib7","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.jhep.2018.03.005","article-title":"EASL clinical practice guidelines on hepatitis E virus infection","volume":"68","author":"Dalton","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2022.105359_bib8","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1053\/j.gastro.2014.08.040","article-title":"A mutation in the hepatitis E virus RNA polymerase promotes its replication and associates with ribavirin treatment failure in organ transplant recipients","volume":"147","author":"Debing","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2022.105359_bib9","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jhep.2016.02.045","article-title":"Update on hepatitis E virology: implications for clinical practice","volume":"65","author":"Debing","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2022.105359_bib10","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jhep.2016.05.002","article-title":"Hepatitis E virus mutations associated with ribavirin treatment failure result in altered viral fitness and ribavirin sensitivity","volume":"65","author":"Debing","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2022.105359_bib11","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/jvh.12515","article-title":"Extra-hepatic replication and infection of hepatitis E virus in neuronal-derived cells","volume":"23","author":"Drave","year":"2016","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2022.105359_bib12","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3390\/v10040149","article-title":"Inhibition of Zika virus replication by silvestrol","volume":"10","author":"Elgner","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2022.105359_bib13","doi-asserted-by":"crossref","first-page":"4838","DOI":"10.1128\/JVI.78.9.4838-4846.2004","article-title":"In vitro replication of hepatitis E virus (HEV) genomes and of an HEV replicon expressing green fluorescent protein","volume":"78","author":"Emerson","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2022.105359_bib14","doi-asserted-by":"crossref","first-page":"9334","DOI":"10.1038\/s41598-021-88727-1","article-title":"Direct conversion of porcine primary fibroblasts into hepatocyte-like cells","volume":"11","author":"Fr\u00e1guas-Eggenschwiler","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2022.105359_bib15","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1128\/MMBR.64.2.239-280.2000","article-title":"Translational control of viral gene expression in eukaryotes","volume":"64","author":"Gale","year":"2000","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"10.1016\/j.antiviral.2022.105359_bib16","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3390\/v10060301","article-title":"Inhibition of hepatitis E virus spread by the natural compound silvestrol","volume":"10","author":"Glitscher","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2022.105359_bib17","series-title":"Translation-targeted Therapeutics for Viral Diseases","author":"Harford","year":"1995"},{"key":"10.1016\/j.antiviral.2022.105359_bib18","doi-asserted-by":"crossref","first-page":"592","DOI":"10.3390\/v10110592","article-title":"Silvestrol inhibits Chikungunya virus replication","volume":"10","author":"Henss","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2022.105359_bib19","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature17978","article-title":"Rocaglates convert DEAD-box protein eIF4A into a sequence-selective translational repressor","volume":"534","author":"Iwasaki","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2022.105359_bib20","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1146\/annurev-virology-100114-055014","article-title":"A cap-to-tail guide to mRNA translation strategies in virus-infected cells","volume":"3","author":"Jan","year":"2016","journal-title":"Annu. Rev. Virol."},{"key":"10.1016\/j.antiviral.2022.105359_bib21","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1056\/NEJMoa1215246","article-title":"Ribavirin for chronic hepatitis E virus infection in transplant recipients","volume":"370","author":"Kamar","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2022.105359_bib22","doi-asserted-by":"crossref","first-page":"5308","DOI":"10.1128\/JVI.02460-05","article-title":"Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses","volume":"80","author":"Koutsoudakis","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2022.105359_bib23","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/j.ebiom.2015.09.018","article-title":"A novel class of small molecule compounds that inhibit hepatitis C virus infection by targeting the prohibitin-CRaf pathway","volume":"2","author":"Liu","year":"2015","journal-title":"EBioMedicine"},{"key":"10.1016\/j.antiviral.2022.105359_bib25","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s11262-019-01641-7","article-title":"Eukaryotic initiation factor 4A (eIF4A) during viral infections","volume":"55","author":"Montero","year":"2019","journal-title":"Virus Gene."},{"key":"10.1016\/j.antiviral.2022.105359_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2021.105012","article-title":"The rocaglate CR-31-B (\u2212) inhibits SARS-CoV-2 replication at non-cytotoxic, low nanomolar concentrations in vitro and ex vivo","volume":"186","author":"M\u00fcller","year":"2021","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2022.105359_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104706","article-title":"Comparison of broad-spectrum antiviral activities of the synthetic rocaglate CR-31-B (\u2212) and the eIF4A-inhibitor Silvestrol","volume":"175","author":"M\u00fcller","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2022.105359_bib28","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.antiviral.2017.12.010","article-title":"Broad-spectrum antiviral activity of the eIF4A inhibitor silvestrol against corona- and picornaviruses","volume":"150","author":"M\u00fcller","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2022.105359_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112653","article-title":"Flavaglines as natural products targeting eIF4A and prohibitins: from traditional Chinese medicine to antiviral activity against coronaviruses","volume":"203","author":"Nebigil","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.antiviral.2022.105359_bib30","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1128\/JVI.02205-13","article-title":"Hepatitis E virus genotype 1 infection of swine kidney cells in vitro is inhibited at multiple levels","volume":"88","author":"Nguyen","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2022.105359_bib31","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nrgastro.2017.150","article-title":"Hepatitis E virus: advances and challenges","volume":"15","author":"Nimgaonkar","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2022.105359_bib32","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3390\/v14030519","article-title":"Rocaglates as antivirals: comparing the effects on viral resistance, anti-coronaviral activity, RNA-clamping on eIF4A and immune cell toxicity","volume":"14","author":"Obermann","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2022.105359_bib33","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-biochem-013118-111042","article-title":"The organizing principles of eukaryotic ribosome recruitment","volume":"88","author":"Pelletier","year":"2019","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.antiviral.2022.105359_bib34","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0166-3542(90)90001-N","article-title":"A three-dimensional model to analyze drug-drug interactions","volume":"14","author":"Prichard","year":"1990","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2022.105359_bib35","doi-asserted-by":"crossref","first-page":"6533","DOI":"10.1002\/anie.201003212","article-title":"Biomimetic photocycloaddition of 3-hydroxyflavones: synthesis and evaluation of rocaglate derivatives as inhibitors of eukaryotic translation","volume":"49","author":"Roche","year":"2010","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.antiviral.2022.105359_bib36","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1021\/jm201263k","article-title":"Synthesis of rocaglamide hydroxamates and related compounds as eukaryotic translation inhibitors: synthetic and biological studies","volume":"55","author":"Rodrigo","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2022.105359_bib37","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1186\/s13059-014-0476-1","article-title":"Transcriptome-wide characterization of the eIF4A signature highlights plasticity in translation regulation","volume":"15","author":"Rubio","year":"2014","journal-title":"Genome Biol."},{"key":"10.1016\/j.antiviral.2022.105359_bib38","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1039\/D0NP00024H","article-title":"Rocaglamide and silvestrol: a long story from anti-tumor to anti-coronavirus compounds","volume":"38","author":"Schulz","year":"2021","journal-title":"Nat. Prod. Rep."},{"key":"10.1016\/j.antiviral.2022.105359_bib39","doi-asserted-by":"crossref","first-page":"6031","DOI":"10.1128\/JVI.00444-13","article-title":"The hepatitis E virus capsid C-terminal region is essential for the viral life cycle: implication for viral genome encapsidation and particle stabilization","volume":"87","author":"Shiota","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2022.105359_bib40","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1128\/JVI.00146-12","article-title":"Adaptation of a genotype 3 hepatitis E virus to efficient growth in cell culture depends on an inserted human gene segment acquired by recombination","volume":"86","author":"Shukla","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2022.105359_bib41","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1073\/pnas.1018878108","article-title":"Cross-species infections of cultured cells by hepatitis E virus and discovery of an infectious virus-host recombinant","volume":"108","author":"Shukla","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2022.105359_bib42","doi-asserted-by":"crossref","first-page":"540","DOI":"10.3390\/microorganisms9030540","article-title":"Targeting the DEAD-box RNA helicase eIF4A with rocaglates\u2014a pan-antiviral strategy for minimizing the impact of future RNA virus pandemics","volume":"9","author":"Taroncher-Oldenburg","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.antiviral.2022.105359_bib43","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1073\/pnas.1912307117","article-title":"Robust hepatitis E virus infection and transcriptional response in human hepatocytes","volume":"117","author":"Todt","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2022.105359_bib44","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1136\/gutjnl-2015-311000","article-title":"In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome","volume":"65","author":"Todt","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.antiviral.2022.105359_bib45","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.coviro.2018.10.001","article-title":"Hepatitis E virus treatment and ribavirin therapy: viral mechanisms of nonresponse","volume":"32","author":"Todt","year":"2018","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.antiviral.2022.105359_bib46","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.antiviral.2018.07.010","article-title":"The natural compound silvestrol inhibits hepatitis E virus (HEV) replication in vitro and in vivo","volume":"157","author":"Todt","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2022.105359_bib47","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3390\/v8100283","article-title":"Mutagenic effects of ribavirin on hepatitis E virus\u2014viral extinction versus selection of fitness-enhancing mutations","volume":"8","author":"Todt","year":"2016","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2022.105359_bib48","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1080\/15476286.2016.1247146","article-title":"New insights into the topology of the scanning ribosome during translation initiation: lessons from viruses","volume":"13","author":"Toribio","year":"2016","journal-title":"RNA Biol."},{"key":"10.1016\/j.antiviral.2022.105359_bib49","doi-asserted-by":"crossref","first-page":"12006","DOI":"10.1002\/chem.201602953","article-title":"Synthesis of aza \u2010rocaglates via ESIPT\u2010mediated (3+2) photocycloaddition","volume":"22","author":"Wang","year":"2016","journal-title":"Chem. Eur J."},{"key":"10.1016\/j.antiviral.2022.105359_bib50","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.tim.2020.07.002","article-title":"Virus\u2013host cell interplay during hepatitis E virus infection","volume":"29","author":"Wi\u00dfing","year":"2021","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.antiviral.2022.105359_bib51","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nature13485","article-title":"RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer","volume":"513","author":"Wolfe","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2022.105359_bib52","unstructured":"World Health Organization (WHO), 2021. (Hepatitis E)."},{"key":"10.1016\/j.antiviral.2022.105359_bib53","doi-asserted-by":"crossref","first-page":"12891","DOI":"10.1021\/jacs.9b06446","article-title":"Intercepted retro-nazarov reaction: syntheses of amidino-rocaglate derivatives and their biological evaluation as eIF4A inhibitors","volume":"141","author":"Zhang","year":"2019","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.antiviral.2022.105359_bib54","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1021\/jacs.8b11477","article-title":"Chemical synthesis enables structural reengineering of aglaroxin C leading to inhibition bias for hepatitis C viral infection","volume":"141","author":"Zhang","year":"2019","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.antiviral.2022.105359_bib55","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.antiviral.2015.10.016","article-title":"Requirement of the eukaryotic translation initiation factor 4F complex in hepatitis E virus replication","volume":"124","author":"Zhou","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2022.105359_bib24","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.antiviral.2019.01.007","article-title":"Cell culture systems for the study of hepatitis E virus","volume":"163","author":"Meister","year":"2019","journal-title":"Antivir. Res."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354222001280?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354222001280?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:36:43Z","timestamp":1759063003000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354222001280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":55,"alternative-id":["S0166354222001280"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2022.105359","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of structurally re-engineered rocaglates as inhibitors against hepatitis E virus replication","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2022.105359","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105359"}}